Only in Titles

Search results for: NSCLC

paperclip

#32746474   2020/08/03 To Up

Prognostic Factors and Survival in Resected T4 Non-small Cell Lung Cancer: Is There Any Difference in the T4 Subgroups?

The eighth edition of the TNM classification revised the subgroups of T4 non-small cell lung cancer (NSCLC). This study aimed to compare the T4-NSCLC subgroups that underwent surgical treatment in terms of mortality, morbidity, survival, and prognostic factors based on the new classification.
Yunus Aksoy, Necati Citak, Cigdem Obuz, Baris Acikmese, Atilla Pekcolaklar, Muzaffer Metin, Adnan Sayar

1529 related Products with: Prognostic Factors and Survival in Resected T4 Non-small Cell Lung Cancer: Is There Any Difference in the T4 Subgroups?

100ug Lyophilized

Related Pathways

paperclip

#32745965   2020/07/31 To Up

KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.

Despite the high prevalence of Kirsten rat sarcoma (KRAS) mutations in non-small cell lung cancer (NSCLC), for a long time it has been defined as an 'undruggable target', with precision medicine not considered as an adequate approach to treat this subgroup of patients. After several years of efforts, preliminary data from early clinical trials have recently demonstrated that direct pharmacological inhibition of KRAS p.G12C mutation is possible, emerging as an effective targeted treatment for about 10-12% of patients with advanced NSCLC, with potential relevant impact on their long-term survival and quality of life. This review reports the current status of KRAS mutations detection in the Italian real-word scenario, summarises the biological basis of KRAS inhibition in NSCLC and provides an updated overview of therapeutic strategies, discussing the potential reasons for past failures and analysing the upcoming challenges related to the advent of new targeted agents in clinical practice.
Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello

2892 related Products with: KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.

1.00 flask

Related Pathways

paperclip

#32745716   2020/07/31 To Up

Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid Cancers: A meta-Analysis with trial sequential analysis.

Albumin-to-alkaline phosphatase ratio (AAPR), a novel and economic serum biomarker, is associated with survival in patients with cancer. This study aimed to evaluate the potential role of AAPR as a prognostic indicator of solid cancers.
Guangwei Tian, Guang Li, Lin Guan, Yue Yang, Nan Li

2309 related Products with: Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid Cancers: A meta-Analysis with trial sequential analysis.

1 kit900 tests100ul1 kit1 kit500 assays 100ul1 kit500 assays100 tests

Related Pathways

paperclip

#32744692   // To Up

Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.

This study aimed to investigate the impact of tumor mutational burden (TMB) and DNA damage repair (DDR) gene alteration on overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients.
H Zhang, Y-M Deng, Z-C Chen, Y-C Tang, S Yang, S-D Zhang, J-M Liang, Y-G Wang, X Wu, R-W Zhang, W-N Feng

1262 related Products with: Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.



Related Pathways

paperclip

#32744429   2020/08/03 To Up

MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.

Previously, we developed a monoclonal antibody (mAb) NJ001 that binds to the antigen SP70 in human non-small cell lung cancer (NSCLC) cells and showed it could inhibit lung adenocarcinoma (AD) growth. Here, we investigated the effect and mechanisms of NJ001 in lung AD metastasis.
Chunrong Gu, Ying Luo, Shichang Zhang, Jian Xu, Jiexin Zhang, Huanyu Ju, Jingping Liu, Lixia Zhang, Yan Zhang, Lei Wu, Erfu Xie, Ting Xu, Shiyang Pan

1251 related Products with: MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.

25 x 2 ml100tests30µg/vial48 assays

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

Error loading info... Pleas try again later.
paperclip

#32742992   // To Up

Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report.

Pembrolizumab is a highly selective IgG4 kappa isotype monoclonal antibody against the programmed cell death-1 (PD-1) molecule. In the treatment of non-small cell lung cancer (NSCLC), pembrolizumab has demonstrated significant efficacy, significant survival outcomes, long-lasting responses, and a good safety profile compared with cytotoxic chemotherapy.
Hong-Beum Kim, Sang-Gon Park, Ran Hong, Seong-Ho Kang, Yong Sub Na

2975 related Products with: Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report.



Related Pathways

paperclip

#32742857   2020/06/28 To Up

Non-Small Cell Lung Carcinoma Presenting With Severe Tracheal Deviation: A Case Report.

Non-small cell lung carcinoma (NSCLC) is usually diagnosed in adults between the ages of 18-35 years. Here, we present a case of a young adult who presented with severe tracheal deviation and was diagnosed with advanced-stage NSCLC with no past medical or social histories; she presented with worsening right arm pain, numbness, and tingling over the course of three weeks. She presented to an urgent care center that prescribed her nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants without any symptom improvement. Her pain continued to worsen, and she went to the emergency department (ED) where an X-ray and CT angiogram were performed revealing a large right lung mass severely compressing the trachea. Biopsies confirmed non-small cell lung cancer and the patient was started on chemotherapy. As clinicians, sometimes we do not pay attention to young patients with nonspecific complaints. This case clearly reflects the importance of proper evaluation of symptoms even though there is low clinical suspicion.
Oluwatoyin Dada, Steven Douedi, Tiffany Purewal, Mohammad Hossain

2373 related Products with: Non-Small Cell Lung Carcinoma Presenting With Severe Tracheal Deviation: A Case Report.



Related Pathways

paperclip

#32742497   2020/07/11 To Up

Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer.

Accumulating evidence suggests that necroptosis, or programmed necrotic cell death, may play a significant role in cancer. We evaluated the expression of key molecules in necroptosis and their association with clinical features and prognosis in NSCLC. A total of 253 NSCLC patients (96 squamous cell carcinoma [SCC] cases and 157 adenocarcinoma [AC] cases) who underwent curative resection were included. Tumor tissues and corresponding normal tissues were investigated for relative mRNA expression levels of , , and . Difference in disease free survival (DFS) was analyzed according to the expression levels of these molecules in tumor tissues. NSCLC tissues had significantly lower expression of , , and than normal tissues ( = 1 x 10, = 8 x 10, and = 4 x 10, respectively). In subgroup analysis, SCCs had significantly lower , , and expression ( = 5 x 10, = 3 x 10, = 1 x 10, respectively), and ACs had significantly lower and expression ( = 0.01 and = 6 x 10, respectively) than normal tissues. Low expression of , , and in tumors was associated with a worse DFS (HR = 1.71, = 0.01; HR = 1.53, = 0.04; and HR = 1.53, = 0.04, respectively) in a multivariate analysis. In SCC, none of the , , and expression was significantly associated with DFS. However, in AC, low expression of , , and was significantly associated with worse DFS (HR = 1.67, = 0.03; HR = 1.70, = 0.03; and HR = 1.81, = 0.02, respectively). Key regulatory genes in necroptosis, , , and , were downregulated in NSCLC, and their lower expression in NSCLC may be used to predict early recurrence after curative resection, especially in AC.
Ji Eun Park, Jang Hyuck Lee, Shin Yup Lee, Mi Jeong Hong, Jin Eun Choi, Sunji Park, Ji Yun Jeong, Eung Bae Lee, Sun Ha Choi, Yong Hoon Lee, Hye Won Seo, Seung Soo Yoo, Jaehee Lee, Seung Ick Cha, Chang Ho Kim, Jae Yong Park

1449 related Products with: Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer.



Related Pathways